MA27935A1 - Modifications stables du maleate d'hydrogene tegaserod - Google Patents

Modifications stables du maleate d'hydrogene tegaserod

Info

Publication number
MA27935A1
MA27935A1 MA28759A MA28759A MA27935A1 MA 27935 A1 MA27935 A1 MA 27935A1 MA 28759 A MA28759 A MA 28759A MA 28759 A MA28759 A MA 28759A MA 27935 A1 MA27935 A1 MA 27935A1
Authority
MA
Morocco
Prior art keywords
hydrogen maleate
tegaserod hydrogen
stable modifications
tegaserod
stable
Prior art date
Application number
MA28759A
Other languages
English (en)
Inventor
Sabine Pfeffer
Christian Vitzling
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34135099&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA27935(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA27935A1 publication Critical patent/MA27935A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Glass Compositions (AREA)
  • Liquid Crystal Substances (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention se rapporte à des formes cristallines du maléate d'hydrogène tegaserod, à leur utilisation dans des compositions pharmaceutiques servant au traitement du syndrome du côlon irritable, du reflux gastrooesophagien pathologique, de la dyspepsie fonctionnelle, et de la constipation ou de la diarrhée chroniques, ainsi qu'à leur production.
MA28759A 2003-07-24 2006-01-27 Modifications stables du maleate d'hydrogene tegaserod MA27935A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48963803P 2003-07-24 2003-07-24

Publications (1)

Publication Number Publication Date
MA27935A1 true MA27935A1 (fr) 2006-06-01

Family

ID=34135099

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28759A MA27935A1 (fr) 2003-07-24 2006-01-27 Modifications stables du maleate d'hydrogene tegaserod

Country Status (24)

Country Link
US (1) US20070112056A1 (fr)
EP (2) EP1651601A1 (fr)
JP (1) JP2006528609A (fr)
KR (1) KR20060040710A (fr)
CN (1) CN1826318A (fr)
AR (1) AR045081A1 (fr)
AU (1) AU2004263285A1 (fr)
BR (1) BRPI0412830A (fr)
CA (1) CA2532351A1 (fr)
CO (1) CO5680418A2 (fr)
EC (1) ECSP066306A (fr)
IL (1) IL172914A0 (fr)
IS (1) IS8321A (fr)
MA (1) MA27935A1 (fr)
MX (1) MXPA06000917A (fr)
MY (1) MY137386A (fr)
NO (1) NO20060915L (fr)
NZ (1) NZ544596A (fr)
PE (1) PE20050253A1 (fr)
RU (1) RU2349585C2 (fr)
SG (1) SG144944A1 (fr)
TN (1) TNSN06024A1 (fr)
TW (1) TW200510302A (fr)
WO (1) WO2005014544A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007514777A (ja) * 2004-10-19 2007-06-07 テバ ファーマシューティカル インダストリーズ リミティド テガセロッドマレエートの精製
JP2008528615A (ja) * 2005-01-31 2008-07-31 ノバルティス アクチエンゲゼルシャフト プロトンポンプ阻害剤により誘発され得る遅延した胃内容排出の処置のための５−ｈｔ４アゴニストの使用
CZ298399B6 (cs) * 2005-05-02 2007-09-19 Zentiva, A. S. Zpusob prípravy 2-[(5-methoxy-1 H-indol-3-yl) methylen]-N-pentylkarbazimidamidu (tegaserodu)
KR20070062504A (ko) * 2005-06-22 2007-06-15 테바 파마슈티컬 인더스트리즈 리미티드 테가세로드 말레이트의 다형태
WO2007119109A2 (fr) * 2005-10-06 2007-10-25 Medichem, S.A. Compositions et procédés utiles pour la préparation de maléate de tégaserod
GB0524668D0 (en) * 2005-12-02 2006-01-11 Novartis Ag Organic compounds
WO2007120924A1 (fr) * 2006-04-17 2007-10-25 Teva Pharmaceutical Industries Ltd. Préparation de maléate de tegaserod exempt de iodure
EP1956002A1 (fr) * 2007-02-07 2008-08-13 Chemo Ibérica, S.A. Nouveaux polymorphes de maléate de tégasérod et leur procédé de préparation
WO2008142445A1 (fr) * 2007-05-17 2008-11-27 Generics [Uk] Limited Procédé de préparation de la forme a du tégasérode

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01242588A (ja) * 1988-03-25 1989-09-27 Chiba Gosei Kenkyusho:Kk ７―シアノメチルチオアセトアミド―７α―メトキシ―３―（１―メチル―１Ｈ―テトラゾール―５―イル）チオメチル―３―セフェム―４―カルボン酸の結晶及びその製造方法
HUT64023A (en) * 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
JPH08291140A (ja) * 1995-04-20 1996-11-05 Teikoku Chem Ind Corp Ltd 易吸収性結晶
NZ509832A (en) * 1998-08-21 2003-11-28 Novartis Ag New oral formulation for 5-HT4 agonists or antagonists
EP1321142A1 (fr) * 2001-12-21 2003-06-25 Novartis AG Forme solide pour l'administration orale du Tégaserode
CN1176077C (zh) * 2003-01-07 2004-11-17 江苏省药物研究所 马来酸替加色罗一水结晶
WO2004085393A1 (fr) * 2003-03-25 2004-10-07 Hetero Drugs Limited Nouvelles formes cristallines de maleate de tegaserod
CA2550886A1 (fr) * 2003-12-16 2005-06-30 Teva Pharmaceutical Industries Ltd. Formes polymorphiques de la base du tegaserod et des sels de celui-ci
US20050272802A1 (en) * 2004-04-22 2005-12-08 Sundaram Venkataraman Process for preparing form I of tegaserod maleate
KR20070062504A (ko) * 2005-06-22 2007-06-15 테바 파마슈티컬 인더스트리즈 리미티드 테가세로드 말레이트의 다형태

Also Published As

Publication number Publication date
MY137386A (en) 2009-01-30
RU2349585C2 (ru) 2009-03-20
SG144944A1 (en) 2008-08-28
RU2006105481A (ru) 2007-09-20
BRPI0412830A (pt) 2006-09-26
AU2004263285A1 (en) 2005-02-17
CA2532351A1 (fr) 2005-02-17
TNSN06024A1 (en) 2007-10-03
AR045081A1 (es) 2005-10-12
ECSP066306A (es) 2006-07-28
TW200510302A (en) 2005-03-16
IL172914A0 (en) 2006-06-11
KR20060040710A (ko) 2006-05-10
JP2006528609A (ja) 2006-12-21
EP1880992A1 (fr) 2008-01-23
MXPA06000917A (es) 2006-03-30
IS8321A (is) 2006-02-22
NO20060915L (no) 2006-04-24
US20070112056A1 (en) 2007-05-17
EP1651601A1 (fr) 2006-05-03
NZ544596A (en) 2009-01-31
WO2005014544A1 (fr) 2005-02-17
CN1826318A (zh) 2006-08-30
PE20050253A1 (es) 2005-06-03
CO5680418A2 (es) 2006-09-29

Similar Documents

Publication Publication Date Title
MA27935A1 (fr) Modifications stables du maleate d'hydrogene tegaserod
MA29692B1 (fr) Derives de la xanthine en tant qu'agonistes selectifs du hm74a
MA30408B1 (fr) Antagonistes du recepteur de l'interleukine 8
MA30558B1 (fr) Antagonistes de recepteurs cgrp monocycliques substitues
MA33920B1 (fr) Modulateurs allosteriques positifs du recepteur m1 a base de quinolinamide
BRPI0410905A (pt) inibidores de p-38
MA31260B1 (fr) 3-imidazolyl-indoles pour le traitement de maladies proliferatives
JO2355B1 (en) Hereditary calcitonin polypeptide receptor antagonists
MA31283B1 (fr) Produits dérivés de 2,3-dihydroimidazo[1,2-c]quinazoline substitués, utiles pour le traitement de troubles hyperlifératifs et de maladies associées à une angiogénèse
ATE556060T1 (de) Monocyclische anilidspirohydantoine als cgrp- rezeptorantagonisten
WO2002060900A8 (fr) Antagonistes vis-a-vis de la fonction mcp-1 et procedes d'utilisation
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
SE0403006D0 (sv) New compounds
MA30077B1 (fr) 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines
MA29723B1 (fr) Composes
SE0104331D0 (sv) Novel compounds
MY133845A (en) Il-8 receptor antagonists
DE602004011204D1 (de) Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten.
WO2005000231A3 (fr) Antagonistes du recepteur il-8
AP1548A (en) Il-8 Receptor Antagonists.
NZ514696A (en) IL-8 receptor antagonists
MX2007001990A (es) Antagonistas del receptor 5-ht7.
AP2002002606A0 (fr) Antagonistes du recepteur de l'interleukine 8
MY143477A (en) Il-8 receptor antagonists
MA29694B1 (fr) Derives de l'imidazopyridine comme ligands du recepteur cannabinoide